...
首页> 外文期刊>Best practice & research: Clinical haematology >Making the diagnosis, the tools, and risk stratification: More than just BCR-ABL
【24h】

Making the diagnosis, the tools, and risk stratification: More than just BCR-ABL

机译:进行诊断,工具和风险分层:不仅仅是BCR-ABL

获取原文
获取原文并翻译 | 示例
           

摘要

The implementation of cytogenetic and molecular techniques into standard clinical practice has improved our ability to more accurately diagnose and monitor CML. Routine peripheral blood BCR-ABL transcript testing can help monitor response, predict outcome, and detect early resistance or poor adherence to TKI therapy. The widely-used Sokal, Hasford and EUTOS clinical risk stratification scores were developed in patients receiving chemotherapy, interferon and imatinib, respectively; their predictive ability in patients receiving next-generation tyrosine kinase inhibitors (TKIs) remains to be established. Newer more sensitive molecular techniques are being developed that may aid in the expanding emphasis on discontinuing therapy in patients with a deep and consistent molecular response. (C) 2016 Published by Elsevier Ltd.
机译:将细胞遗传学和分子技术应用于标准临床实践中,提高了我们更准确地诊断和监测CML的能力。常规外周血BCR-ABL转录本测试可帮助监测反应,预测结果并检测对TKI治疗的早期耐药性或依从性差。分别在接受化疗,干扰素和伊马替尼治疗的患者中建立了广泛使用的Sokal,Hasford和EUTOS临床风险分层评分。它们在接受下一代酪氨酸激酶抑制剂(TKIs)的患者中的预测能力仍有待建立。正在开发更新的更敏感的分子技术,这可能有助于扩大对具有深刻而一致的分子反应的患者中止治疗的重视。 (C)2016由Elsevier Ltd.出版

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号